Tag: China
Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...
Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.
WuXi XDC and AbTis to Collaborate in the Development and Manufacturing...
Chinese WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, a Contract Research, Development and Manufacturing Organization focusing on end-to-end bioconjugates services, and...
Sacituzumab Govitecan Approved in China for Second-Line Metastatic Triple-Negative Breast Cancer
China's National Medical Products Administration (NMPA) has approved sacituzumab govitecan (Trodelvy®; Gilead Sciences) for the treatment of adult patients with unresectable locally advanced or metastatic...
Anti-Nectin-4 ADC Drug Receives IND Approval; Phase I Studies Started
The Center for Drug Evaluation (CDE) of China National Medical Products Administration has approved the investigational new drug application (IND) for 9MW2821, an anti-Nectin-4...
MabPlex awards CloudWorks4All with Enterprise Resource Planning (ERP) Contract
MabPlex USA, the North American subsidiary, China-based MabPlex (Yantai, Shandong Province, China) has contracted systems integrator CloudWorks4All, a leading life science and cloud ERP...
Real World-Ready
The stated aim of my old school is to make pupils ‘real world-ready’. This is a project conceived as one of boundless ambition in...
MabPlex Opens New Phase III and Commercial Manufacturing Facility
MabPlex International, a fully integrated Contract Development and Manufacturing Organization (CDMO) with sites in China and the United States, has inaugurated their new manufacturing...
Benefitting from the Worldwide Supply Chain in the development of Antibody-drug...
Timing is everything.
Just over a decade ago, the pharmaceutical industry and R&D in China was dominated by generics and plagued with insufficient technical capacity...
New Reports Suggests Antibody-drug Conjugates Market to Set Phenomenal Growth in...
A new market research report published in late June by HTF market Intelligence Consulting, suggests that the Antibody-drug conjugates (ADC) Market in China is...
Andrew Huang: “ADC’s Are Among the most Powerful Options to...
With a population of 1.4 billion and a rapidly expanding economy, China has become a manufacturing powerhouse. In addition, China is pursuing a...
